Publications by authors named "Stephen B Fox"

100Publications

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

NPJ Breast Cancer 2020 12;6:17. Epub 2020 May 12.

21Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-020-0156-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217863PMC
May 2020

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

J Pathol 2020 04 9;250(5):667-684. Epub 2020 Apr 9.

Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, TN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.5406DOI Listing
April 2020

Emerging entities in NUTM1-rearranged neoplasms.

Genes Chromosomes Cancer 2020 06 25;59(6):375-385. Epub 2020 Feb 25.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22838DOI Listing
June 2020

Improved next-generation sequencing pre-capture library yields and sequencing parameters using on-bead PCR.

Biotechniques 2020 01 11;68(1):48-51. Epub 2019 Dec 11.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/btn-2019-0059DOI Listing
January 2020

Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.

Cytopathology 2020 03 11;31(2):90-95. Epub 2020 Jan 11.

Department of Pathology at Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12795DOI Listing
March 2020

E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

iScience 2019 Dec 2;22:1-15. Epub 2019 Nov 2.

Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia; Department of Clinical Pathology, University of Melbourne, Parkville, VIC 3010, Australia; Department of Biochemistry and Molecular Biology, Monash University, Melbourne 3800, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.isci.2019.10.065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864340PMC
December 2019

Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

J Thorac Oncol 2018 09;13(9):e185-e186

Department of Pathology, Peter MacCallum Cancer Center, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183059
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.04.029DOI Listing
September 2018

Canary: an atomic pipeline for clinical amplicon assays.

BMC Bioinformatics 2017 Dec 15;18(1):555. Epub 2017 Dec 15.

Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-017-1950-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732437PMC
December 2017

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.

J Thorac Oncol 2018 03 23;13(3):367-376. Epub 2017 Nov 23.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173305
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.11.112DOI Listing
March 2018

LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.

Oncotarget 2017 Oct 28;8(48):83626-83636. Epub 2017 Jul 28.

Department of Pathology, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre, Melbourne, VIC 3000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18886DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663541PMC
October 2017

Ductal Carcinoma Biology, Biomarkers, and Diagnosis.

Front Oncol 2017 23;7:248. Epub 2017 Oct 23.

The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660056PMC
October 2017

Precision oncology using a clinician-directed, tailored approach to molecular profiling.

Asia Pac J Clin Oncol 2018 Feb 30;14(1):84-90. Epub 2017 Oct 30.

Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12787DOI Listing
February 2018

BRCA2 carriers with male breast cancer show elevated tumour methylation.

BMC Cancer 2017 09 11;17(1):641. Epub 2017 Sep 11.

Molecular Pathology Research and Development Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3632-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594583PMC
September 2017

HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.

Pathology 2017 Oct 18;49(6):575-581. Epub 2017 Aug 18.

Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2017.05.009DOI Listing
October 2017

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Nov;24(6):311-335

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000161DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638696PMC
November 2017

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Authors:
Shona Hendry Roberto Salgado Thomas Gevaert Prudence A Russell Tom John Bibhusal Thapa Michael Christie Koen van de Vijver M V Estrada Paula I Gonzalez-Ericsson Melinda Sanders Benjamin Solomon Cinzia Solinas Gert G G M Van den Eynden Yves Allory Matthias Preusser Johannes Hainfellner Giancarlo Pruneri Andrea Vingiani Sandra Demaria Fraser Symmans Paolo Nuciforo Laura Comerma E A Thompson Sunil Lakhani Seong-Rim Kim Stuart Schnitt Cecile Colpaert Christos Sotiriou Stefan J Scherer Michail Ignatiadis Sunil Badve Robert H Pierce Giuseppe Viale Nicolas Sirtaine Frederique Penault-Llorca Tomohagu Sugie Susan Fineberg Soonmyung Paik Ashok Srinivasan Andrea Richardson Yihong Wang Ewa Chmielik Jane Brock Douglas B Johnson Justin Balko Stephan Wienert Veerle Bossuyt Stefan Michiels Nils Ternes Nicole Burchardi Stephen J Luen Peter Savas Frederick Klauschen Peter H Watson Brad H Nelson Carmen Criscitiello Sandra O'Toole Denis Larsimont Roland de Wind Giuseppe Curigliano Fabrice André Magali Lacroix-Triki Mark van de Vijver Federico Rojo Giuseppe Floris Shahinaz Bedri Joseph Sparano David Rimm Torsten Nielsen Zuzana Kos Stephen Hewitt Baljit Singh Gelareh Farshid Sibylle Loibl Kimberly H Allison Nadine Tung Sylvia Adams Karen Willard-Gallo Hugo M Horlings Leena Gandhi Andre Moreira Fred Hirsch Maria V Dieci Maria Urbanowicz Iva Brcic Konstanty Korski Fabien Gaire Hartmut Koeppen Amy Lo Jennifer Giltnane Marlon C Rebelatto Keith E Steele Jiping Zha Kenneth Emancipator Jonathan W Juco Carsten Denkert Jorge Reis-Filho Sherene Loi Stephen B Fox

Adv Anat Pathol 2017 Sep;24(5):235-251

Departments of *Pathology §§§Medical Oncology, Peter MacCallum Cancer Centre, Melbourne †The Sir Peter MacCallum Department of Oncology Departments of **Pathology ∥∥Medicine, University of Melbourne ¶¶Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville #Department of Anatomical Pathology, St Vincent's Hospital Melbourne, Fitzroy ††Department of Medical Oncology, Austin Health ‡‡Olivia Newton-John Cancer Research Institute, Heidelberg §§School of Cancer Medicine, La Trobe University, Bundoora §§§§§Centre for Clinical Research and School of Medicine, The University of Queensland ∥∥∥∥∥Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane §§§§§§§§§§The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst ∥∥∥∥∥∥∥∥∥∥Australian Clinical Labs, Bella Vista ‡‡‡‡‡‡‡‡‡‡‡‡Directorate of Surgical Pathology, SA Pathology §§§§§§§§§§§§Discipline of Medicine, Adelaide University, Adelaide, Australia ***********Department of Surgical Oncology, Netherlands Cancer Institute †††††††††††††Department of Pathology ##Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands ###Université Paris-Est ****INSERM, UMR 955 ††††Département de pathologie, APHP, Hôpital Henri-Mondor, Créteil ∥∥∥∥∥∥∥∥∥Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Inserm U1018, Université-Paris Sud, Université Paris-Saclay ¶¶¶¶¶¶¶¶¶¶INSERM Unit U981, and Department of Medical Oncology, Gustave Roussy, Villejuif ##########Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre †††††††Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre ‡‡‡‡‡‡‡University of Auvergne UMR1240, Clermont-Ferrand, France ‡‡‡‡Department of Medicine, Clinical Division of Oncology §§§§Institute of Neurology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna ††††††††††††††Institute of Pathology, Medical University of Graz, Austria ∥∥∥∥European Institute of Oncology ¶¶¶¶School of Medicine ######Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan ¶¶¶¶¶¶¶¶¶¶¶¶¶Department of Surgery, Oncology and Gastroenterology, University of Padova #############Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy †††††Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona †††††††††††Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain §Department of Pathology and TCRU, GZA ¶¶¶Department of Pathology, GZA Ziekenhuizen, Antwerp ∥Laboratory of Experimental Urology, Department of Development and Regeneration, KU Leuven ‡‡‡‡‡‡‡‡‡‡‡Department of Pathology, University Hospital Leuven, Leuven, Belgium ¶Department of Pathology, AZ Klina, Brasschaat ††††††Department of Pathology, GZA Ziekenhuizen, Sint-Augustinus, Wilrijk ∥∥∥Molecular Immunology Unit ‡‡‡‡‡‡Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles ‡Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet **************European Organisation for Research and Treatment of Cancer (EORTC) Headquarters *******Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium §§§§§§§Department of Surgery, Kansai Medical School, Hirakata, Japan #######Severance Biomedical Science Institute and Department of Medical Oncology, Yonsei University College of Medicine, Seoul, South Korea ∥∥∥∥∥∥∥∥Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center ¶¶¶¶¶¶¶¶Institute of Oncology, Gliwice Branch, Gliwice, Poland ‡‡‡‡‡‡‡‡‡‡‡‡‡‡Pathology and Tissue Analytics, Roche Innovation Centre Munich, Penzberg †††††††††Institute of Pathology, Charité Universitätsmedizin Berlin ‡‡‡‡‡‡‡‡‡VMscope GmbH, Berlin ¶¶¶¶¶¶¶¶¶German Breast Group GmbH, Neu-Isenburg, Germany **********Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency ††††††††††Department of Biochemistry and Microbiology, University of Victoria, Victoria Departments of ‡‡‡‡‡‡‡‡‡‡Medical Genetics #########Pathology and Laboratory Medicine ¶¶¶¶¶¶¶¶¶¶¶Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC ###########Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada §§§§§§§§§§§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, Doha, Qatar ‡‡‡‡‡‡‡‡Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center §§§§§§§§Warren Alpert Medical School of Brown University, Providence ¶¶¶¶¶National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA †††Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Departments of ‡‡‡Pathology, Microbiology and Immunology ########Department of Medicine, Vanderbilt University Medical Centre *********Vanderbilt Ingram Cancer Center, Nashville §§§§§§§§§Department of Pathology, Yale University School of Medicine, New Haven ∥∥∥∥∥∥∥∥∥∥∥Department of Oncology, Montefiore Medical Centre, Albert Einstein College of Medicine ∥∥∥∥∥∥∥Montefiore Medical Center ¶¶¶¶¶¶¶The Albert Einstein College of Medicine, Bronx, NY ********Department of Pathology, Brigham and Women's Hospital #####Cancer Research Institute and Department of Pathology, Beth Israel Deaconess Cancer Center ******Harvard Medical School ¶¶¶¶¶¶¶¶¶¶¶¶Division of Hematology-Oncology, Beth Israel Deaconess Medical Center ††††††††Department of Cancer Biology ‡‡‡‡‡‡‡‡‡‡‡‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO ‡‡‡‡‡Department of Cancer Biology, Mayo Clinic, Jacksonville, FL ∥∥∥∥∥∥Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN ¶¶¶¶¶¶Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA ††††††††††††Department of Pathology, New York University Langone Medical Centre ############New York University Medical School *************Perlmutter Cancer Center §§§§§§§§§§§§§Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University ***************Department of Pathology, Memorial Sloan-Kettering Cancer Center ####Departments of Radiation Oncology and Pathology, Weill Cornell Medicine, New York, NY *****Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX ∥∥∥∥∥∥∥∥∥∥∥∥Pathology Department, Stanford University Medical Centre, Stanford ∥∥∥∥∥∥∥∥∥∥∥∥∥∥Department of Pathology, Stanford University, Palo Alto ***Department of Pathology, School of Medicine, University of California, San Diego §§§§§§§§§§§§§§Research Pathology, Genentech Inc., South San Francisco, CA *************Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda ¶¶¶¶¶¶¶¶¶¶¶¶¶¶Translational Sciences, MedImmune, Gaithersberg, MD §§§§§§Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover ##############Translational Medicine, Merck & Co. Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAP.0000000000000162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564448PMC
September 2017

Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.

Asia Pac J Clin Oncol 2017 Aug 12;13(4):296-303. Epub 2017 Jul 12.

Flinders Medical Centre and Flinders University, South Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12699DOI Listing
August 2017

The fibrinolysis inhibitor α-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer.

Growth Factors 2017 06 11;35(2-3):61-75. Epub 2017 Jul 11.

a Tumour Angiogenesis and Microenvironment Program , Peter MacCallum Cancer Centre , Melbourne , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08977194.2017.1349765DOI Listing
June 2017

Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.

Pathology 2017 Aug 30;49(5):457-464. Epub 2017 Jun 30.

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, St Leonards, NSW, Australia; Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, NSW, Australia; University of Sydney, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2017.05.004DOI Listing
August 2017

Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features.

Clin Cancer Res 2017 Sep 13;23(17):5210-5217. Epub 2017 Jun 13.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0743DOI Listing
September 2017

GATA3 expression in triple-negative breast cancers.

Histopathology 2017 Jul 19;71(1):63-71. Epub 2017 Apr 19.

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13187DOI Listing
July 2017

Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.

Pathology 2017 Feb 31;49(2):141-155. Epub 2016 Dec 31.

Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Vic, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2016.10.010DOI Listing
February 2017

Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program.

Pathology 2016 Oct 25;48(6):535-42. Epub 2016 Aug 25.

Healthscope Pathology, Norwest Private Hospital, Bella Vista, NSW, Australia; Western Sydney University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2016.05.007DOI Listing
October 2016

Apatinib for the treatment of gastric cancer.

Expert Rev Gastroenterol Hepatol 2016 Aug 15;10(8):887-92. Epub 2016 Jul 15.

b Unit of Molecular Therapy and Pharmacogenomic , ASST Cremona , Cremona , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2016.1209407DOI Listing
August 2016

Is it time for everolimus-based combination in castration-resistant prostate cancer?

Future Oncol 2016 Aug 2;12(16):1849-52. Epub 2016 Jun 2.

Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0136DOI Listing
August 2016

Assessing Tumor Angiogenesis in Histological Samples.

Methods Mol Biol 2016 ;1430:3-33

Department of Pathology, Peter MacCallum Cancer Centre, 2 St Andrews Place, Melbourne, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-3628-1_1DOI Listing
December 2017

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

Eur J Cancer 2016 07 7;61:111-21. Epub 2016 May 7.

Molecular Therapy and Pharmacogenomic Unit, ASST di Cremona, Viale Concordia 1, 26100, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.04.002DOI Listing
July 2016

Reply to the Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast.

Histopathology 2016 09 5;69(3):523-4. Epub 2016 May 5.

Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12968DOI Listing
September 2016

The cancer genetics and pathology of male breast cancer.

Histopathology 2016 Jan;68(1):110-8

Department of Pathology, Peter MacCallum Cancer Centre, Department of Pathology and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12862DOI Listing
January 2016

Ductal carcinoma in situ - update on risk assessment and management.

Histopathology 2016 Jan;68(1):96-109

Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12796DOI Listing
January 2016

Copy number analysis of ductal carcinoma in situ with and without recurrence.

Mod Pathol 2015 Sep 19;28(9):1174-84. Epub 2015 Jun 19.

Cancer Genetics Laboratory, Peter MacCullum Cancer Centre, East Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2015.75DOI Listing
September 2015

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?

Oncoscience 2015 5;2(6):567-9. Epub 2015 Jun 5.

U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506357PMC
http://dx.doi.org/10.18632/oncoscience.168DOI Listing
August 2015

In Response.

J Thorac Oncol 2015 Aug;10(8):e85

Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000604DOI Listing
August 2015

Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.

BMC Cancer 2015 Jul 8;15:506. Epub 2015 Jul 8.

Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1522-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494690PMC
July 2015

Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours.

Histopathology 2016 Feb 7;68(3):367-77. Epub 2015 Aug 7.

Department of Pathology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12765DOI Listing
February 2016

Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer.

PLoS One 2015 25;10(6):e0128861. Epub 2015 Jun 25.

Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Pathology, University of Melbourne, Parkville, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128861PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481506PMC
March 2016

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.

Breast Cancer Res 2015 Jun 16;17:80. Epub 2015 Jun 16.

Department of Pathology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-015-0586-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469314PMC
June 2015

Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.

J Natl Cancer Inst Monogr 2015 May;2015(51):64-6

U.O. Multidisciplinare di Patologia Mammaria/ US Terapia Molecolare (DG, MRC, LZ, GB, MF, FB, MEV, MM, CS, MA, SA, GA, ABo), and Anatomia Patologica (GF, RB), Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Oncologia Medica, Università di Brescia, Spedali Civili di Brescia, Brescia, Italy (ABe, GB); Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK (ALH); Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia (SBF).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv018DOI Listing
May 2015

Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.

J Natl Cancer Inst Monogr 2015 May;2015(51):1-3

U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica (DG, AB), Direzione Sanitaria (CR), A.O. Istituti Ospitalieri di Cremona, Cremona, Italy (DG, AB); Department of Anatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia (SBF); Thomas Jefferson University Hospital, Philadelphia, PA (MC); San Raffaele - Scientific Institute, Milan, Italy (GB); Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy (AZ); Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT (CH); Division of Pathology, European Institute of Oncology, Milan, Italy (MB); Department of Policy Analysis and Public Management, Research Center on Health and Social Care Management, CERGAS, SDA Bocconi School of Management, Bocconi University, Milan, Italy (RT); Health Technology Assessment - Regione Lombardia, Italy (MT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv022DOI Listing
May 2015

Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.

J Thorac Oncol 2015 Apr;10(4):611-8

*Department of Pathology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia; †Department of Anatomical Pathology, St Vincent's Hospital, Victoria Parade, Fitzroy, Victoria, 3065, Australia; ‡Department of Surgery, St Vincent's Hospital, The University of Melbourne, Victoria Parade, Fitzroy, Victoria, 3065, Australia; §Ventana Medical Systems Inc, 1910 Innovation Park Drive, Tucson, AZ 85755; and ‖Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000465DOI Listing
April 2015

Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous.

J Clin Pathol 2015 May 23;68(5):362-7. Epub 2015 Feb 23.

Department of Pathology, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2014-202824DOI Listing
May 2015

The genomic landscape of phaeochromocytoma.

J Pathol 2015 May 2;236(1):78-89. Epub 2015 Feb 2.

The Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; The Department of Pathology, University of Melbourne, Parkville, VIC, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4503DOI Listing
May 2015

Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors.

Cell Rep 2014 Dec 20;9(5):1781-1797. Epub 2014 Nov 20.

Differentiation and Transcription Laboratory, Peter MacCallum Cancer Centre (PMCC), East Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3000, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2014.10.059DOI Listing
December 2014

Diagnostic issues with significant tumour displacement in breast biopsies.

J Clin Pathol 2014 Dec 11;67(12):1110-1. Epub 2014 Sep 11.

Department of Pathology, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2014-202450DOI Listing
December 2014

Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?

Expert Opin Ther Targets 2014 Jun 20;18(6):665-78. Epub 2014 Mar 20.

University of Brescia Medical School, Department of Molecular and Translational Medicine, Section of Pharmacology , Brescia , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.2014.898064DOI Listing
June 2014

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Asia Pac J Clin Oncol 2014 Sep 9;10(3):261-5. Epub 2014 May 9.

Hunter Area Pathology Service, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12201DOI Listing
September 2014

HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?

Pathology 2014 Apr;46(3):184-7

1PathWest Laboratory Medicine, Perth 2School of Pathology and Laboratory Medicine, University of Western Australia, Perth 3School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, WA 4Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne 5Department of Pathology and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0000000000000075DOI Listing
April 2014

Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Nat Rev Cancer 2014 Mar;14(3):159-72

1] Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. [2] Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3010, Australia. [3] Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3677DOI Listing
March 2014

Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.

Mol Oncol 2014 May 24;8(3):656-68. Epub 2014 Jan 24.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; Royal Women's Hospital, Parkville, Victoria 3052, Australia; Department of Medical Biology, University of Melbourne, Parkville, Victoria 3052, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400120PMC
May 2014

Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer.

Mod Pathol 2014 09 24;27(9):1223-30. Epub 2014 Jan 24.

1] Department of Pathology, Peter MacCallum Cancer Center, Melbourne, Australia [2] Department of Pathology and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.231DOI Listing
September 2014

Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.

Int J Cancer 2014 Aug 30;135(4):887-95. Epub 2014 Jan 30.

Department of Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia; University of Melbourne, Australia; Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.28727DOI Listing
August 2014